Neurosense Therapeutics Ltd (NRSN) Stock Price, Quote & News

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 799 6183

Website: www.neurosense-tx.com

Address:

Building B, 11 HaMenofim Street, Herzliya, Israel

JohnnyBoy272 Jul. 9 at 5:02 AM

$NRSN Maybe I am reading into this too much, but last ROTH report, stated Phase 3 trial would need $80 million. However in the latest webinar, the CFO did not want to answer that question, but gave a ballpark figure of dozens of millions? A bit strange to me

0 · Reply

Holla4adolla1 Jul. 9 at 3:48 AM

$NRSN Meeting highlights from Roth Webinar • Phase 3 PARAGON remains the top priority. • Management is pursuing three parallel funding pathways with a goal of securing funding within 3–4 months. • Health Canada NOC/c and a U.S. NDA remain key regulatory objectives following Phase 3. • Management reaffirmed confidence in PrimeC, highlighting previously reported positive ALS and Alzheimer's biomarker data. • No partnership or regulatory announcements were made during the webinar. Bottom line: Funding remains the immediate focus. A strategic partnership, financing announcement, and progress toward Health Canada NOC/c and a U.S. NDA are the major catalysts we are waiting for.

0 · Reply

Wizzard88 Jul. 9 at 12:30 AM

$NRSN We had % 0.25 gain today!! 🤣🤣🤣🤣

0 · Reply

rml360 Jul. 8 at 6:23 PM

$NRSN listen from the 44 minute mark, multiple partners and canada update https://roth.zoom.us/rec/play/FCNLWBcsM0i1moPus4-LDaFjU5PR-r5VTLBOPZkZSZgwRq4ndW5KZuV6y5C4uiTImDMIYRpLpiiOxoTY.UlIGQSaSw9lMJoUM?accessLevel=meeting&canPlayFromShare=true&from=share_recording_detail&continueMode=true&oldStyle=true&componentName=rec-play&originRequestUrl=https%3A%2F%2Froth.zoom.us%2Frec%2Fshare%2FbcOkDPE27mjEGkVQH1XtKOYZkpWqISFXnROqsWXA-8d0VQ4j-7JIR4mPq2Lhabme.38LELEhLZtvAc3iu

2 · Reply

Wizzard88 Jul. 8 at 5:36 PM

$NRSN So are we cooked ?!

0 · Reply

Wizzard88 Jul. 8 at 3:44 PM

$NRSN So this meeting hosted by Boobalan guy from Roth ! Whose target is 3 ! 🤔🧐

0 · Reply

Stekli27 Jul. 8 at 3:36 PM

$NRSN Can someone summarize what they’re talking about today? Any signs of a potential partnership?

0 · Reply

rml360 Jul. 8 at 12:58 PM

$NRSN any guesses on share price on canada accelerated approval with current P2 data, along with committment for p3 confirmatory? I am thinking 5 but open to suggestions, I would exit my position completely

3 · Reply

bin1adin Jul. 6 at 11:25 PM

$NRSN didnt they already have a talk with roth capital . I have the whole 35 page journal that rorh capital made after their talk in march.

0 · Reply

Speculator2 Jul. 6 at 10:26 PM

$NRSN My take on this upcoming webinar - It looks more like an investor-focused event. Roth Capital Partners is a well-established institutional investment bank specializing in small and mid-cap growth companies. They run investor conferences and webinars specifically to connect publicly listed companies with institutional investors who are evaluating positions. This is not a community event or a scientific conference. This is a direct institutional investor outreach event with both the CEO and the CFO are in attendance. That question "can PrimeC be a blockbuster drug" is not a question you ask at a patient community event or a scientific conference but one for institutional investors evaluating commercial potential. Someone at Roth Capital believes the answer is potentially yes and wants institutional investors to hear the case. https://roth.zoom.us/webinar/register/WN_PuzoRxSTQkW1NAn-WdeBRA#/registration

0 · Reply

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NRSN

Jun 29, 2026, 9:30 AM EDT - 9 days ago

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NRSN

Jun 25, 2026, 9:20 AM EDT - 13 days ago

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

NRSN

Jun 22, 2026, 9:00 AM EDT - 16 days ago

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NRSN

Jun 11, 2026, 9:00 AM EDT - 27 days ago

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NRSN

Jun 9, 2026, 9:00 AM EDT - 4 weeks ago

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NRSN

May 4, 2026, 7:00 AM EDT - 2 months ago

NeuroSense Therapeutics Slides: Corporate presentation

Apr 28, 2026, 2:30 PM EDT - 2 months ago

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NRSN

Apr 14, 2026, 7:00 AM EDT - 3 months ago

NeuroSense Therapeutics Slides: Corporate presentation

Apr 6, 2026, 9:20 AM EDT - 3 months ago

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NRSN

Apr 3, 2026, 10:02 AM EDT - 3 months ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NRSN

Mar 31, 2026, 9:30 AM EDT - 3 months ago

NeuroSense Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:30 AM EDT - 3 months ago

NeuroSense Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:20 AM EDT - 3 months ago

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NRSN

Mar 24, 2026, 9:00 AM EDT - 3 months ago

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

NRSN

Mar 18, 2026, 8:00 AM EDT - 4 months ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

NRSN

Mar 16, 2026, 11:33 AM EDT - 4 months ago

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

NRSN

Mar 11, 2026, 7:00 AM EDT - 4 months ago

NeuroSense Therapeutics Slides: Corporate presentation

Mar 9, 2026, 11:07 AM EDT - 4 months ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NRSN

Feb 18, 2026, 9:05 AM EST - 5 months ago

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NRSN

Feb 9, 2026, 9:20 AM EST - 5 months ago

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NRSN

Jan 29, 2026, 7:00 AM EST - 5 months ago

NeuroSense Therapeutics Registration statement: Registration Filing

Jan 21, 2026, 8:30 AM EST - 6 months ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

NRSN

Jan 8, 2026, 8:45 AM EST - 6 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NRSN

Jan 4, 2026, 7:00 AM EST - 6 months ago

NeuroSense Therapeutics Slides: Corporate presentation

Dec 22, 2025, 9:17 AM EST - 7 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NRSN

Dec 9, 2025, 7:00 AM EST - 7 months ago

NeuroSense Therapeutics Slides: Corporate Presentation

Dec 8, 2025, 8:30 AM EST - 7 months ago

NeuroSense Therapeutics Transcript: Status Update

Dec 4, 2025, 7:30 AM EST - 7 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NRSN

Nov 24, 2025, 9:56 AM EST - 8 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NRSN

Nov 3, 2025, 9:15 AM EST - 8 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

NRSN

Oct 28, 2025, 8:00 AM EDT - 9 months ago

NeuroSense Therapeutics Registration statement: Registration Filing

Oct 6, 2025, 9:00 AM EDT - 9 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NRSN

Sep 10, 2025, 2:30 PM EDT - 10 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NRSN

Sep 4, 2025, 8:49 AM EDT - 10 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NRSN

Aug 1, 2025, 9:00 AM EDT - 1 year ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

NRSN

Jul 31, 2025, 6:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q2 2025

Jul 22, 2025, 8:42 AM EDT - 1 year ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

NRSN

May 7, 2025, 8:45 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NRSN

Apr 24, 2025, 9:09 AM EDT - 1 year ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NRSN

Apr 9, 2025, 8:30 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NRSN

Apr 7, 2025, 5:14 PM EDT - 1 year ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NRSN

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Earnings release: Q4 2024

Apr 7, 2025, 4:00 PM EDT - 1 year ago

NeuroSense Therapeutics Annual report: Q4 2024

Apr 4, 2025, 9:10 AM EDT - 1 year ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NRSN

Mar 17, 2025, 8:30 AM EDT - 1 year ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NRSN

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NRSN

Dec 26, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NRSN

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NRSN

Dec 18, 2024, 8:00 AM EST - 1 year ago

NeuroSense Therapeutics Earnings release: Q3 2024

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NRSN

Dec 6, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NRSN

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NRSN

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NRSN

Nov 19, 2024, 7:00 AM EST - 1 year ago

NeuroSense Therapeutics Registration statement: Registration Filing

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

NRSN

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NRSN

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NRSN

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NRSN

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NRSN

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NRSN

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NRSN

Aug 30, 2024, 4:30 PM EDT - 2 years ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NRSN

Aug 7, 2024, 2:00 PM EDT - 2 years ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NRSN

JohnnyBoy272 Jul. 9 at 5:02 AM

0 · Reply

Holla4adolla1 Jul. 9 at 3:48 AM

0 · Reply

Wizzard88 Jul. 9 at 12:30 AM

$NRSN We had % 0.25 gain today!! 🤣🤣🤣🤣

0 · Reply

rml360 Jul. 8 at 6:23 PM

2 · Reply

Wizzard88 Jul. 8 at 5:36 PM

$NRSN So are we cooked ?!

0 · Reply

Wizzard88 Jul. 8 at 3:44 PM

$NRSN So this meeting hosted by Boobalan guy from Roth ! Whose target is 3 ! 🤔🧐

0 · Reply

Stekli27 Jul. 8 at 3:36 PM

$NRSN Can someone summarize what they’re talking about today? Any signs of a potential partnership?

0 · Reply

rml360 Jul. 8 at 12:58 PM

3 · Reply

bin1adin Jul. 6 at 11:25 PM

$NRSN didnt they already have a talk with roth capital . I have the whole 35 page journal that rorh capital made after their talk in march.

0 · Reply

Speculator2 Jul. 6 at 10:26 PM

0 · Reply

Wizzard88 Jul. 6 at 8:12 PM

$NRSN But seriously who is the possible partner ?

0 · Reply

JohnnyBoy272 Jul. 6 at 7:55 PM

$NRSN Their last partnership opportunity was in August 2024, they said they were in the late stages They blueballed all their shareholders each quarter saying it is still in the talks but they were some third party disagreements In 2026, on their earnings report they buried two sentenced that the partnership talk has concluded They did not release any news about this, nor why the partnership talks ended Till this day we have no clue why it ended, I have reached out but they ignored my message But if I tell them about my mother needing to go a compound pharmacy to make their drug, they will give a full explanation why I shouldn’t even though her neuro doctor recommended it

0 · Reply

JohnnyBoy272 Jul. 6 at 7:41 PM

$NRSN They will dilute since they need to cover their expenses If you wanna ask about real catalysts, look at their previous analysis, they are still doing cohort analysis on a trial that concluded at 2024 They will reverse split, they do not care. They have done multiple raises using the ATM to pay their operating expenses, look at 2025, their cash balance being above $200,000 was because they kept diluting They do not care about their shareholders, look at their website, their IR presentation was last updated in May, and their website was last update in January

1 · Reply

Mac0982 Jul. 6 at 7:29 PM

$NRSN what is there plan to get this above $1? i mean why cant it stay there for over 30 days? Very promising company. They are out of compliance are they not?

0 · Reply

Wizzard88 Jul. 6 at 4:09 PM

$NRSN The only garbage is red is this one in my list !!😞

0 · Reply

Wizzard88 Jul. 6 at 3:36 PM

$NRSN As I said before whenever I sell this shit then it will fly !! 😂😅

0 · Reply

KoalaFlipper Jul. 6 at 1:48 PM

$NRSN https://www.prnewswire.com/news-releases/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatment-a-quest-to-outrun-als-302818300.html

1 · Reply

KoalaFlipper Jul. 6 at 1:41 PM

$NRSN 🙏🐂🚀📈

0 · Reply

JohnnyBoy272 Jul. 6 at 12:13 PM

$NRSN I really want to see their earnings report, I feel like they have beaten their ATM to death these past two quarters to cover their operating expenses I do not think there is any left large amounts in the tank, in January they announced $6.25 million ATM program, realistically by Q3 this should be gone if each quarter is around $2.5 million historically. If they announce another bridge type financing, we are kind of fucked. If they don’t, I would infer the partner, buyout or some strategic development is near the corner They need the financing news, otherwise this is going to R/S and lose all its credibility. I know Alon loves jumping the gun, but he’s been fairly quiet this time around

0 · Reply

LibertarianTreehugger Jul. 5 at 5:15 PM

NeuroSense Just Did Something Few ALS Drug Developers Have Done: https://jlsfund.substack.com/p/neurosense-just-did-something-few $NRSN

0 · Reply

Stekli27 Jul. 3 at 7:05 PM

$NRSN I think it‘s gonna be a very interesting year 🎢🎢😱

0 · Reply

Speculator2 Jul. 3 at 12:33 AM

$NRSN The NeuroDex PR is the most important scientific document published this week, more important than the NeuroSense PR itself because it provides the validation foundation that gives the NeuroSense finding its full scientific context. Published the day after Taylor's critique went public, it answers his concerns with specific data, specific p-values, and a peer-reviewed publication reference. Whether this was deliberately timed as a response to Taylor or was independently planned and happened to coincide is less important than what it contains. Taylor's critique has now been met with more and better public evidence than existed before he raised it. The scientific record around NDE-TDP-43 as a biomarker is measurably stronger now than it was when he posted his first comment. That's a great outcome for the science, for NeuroSense, and ironically for Taylor's goal of ensuring the field has rigorous biomarker standards before drawing clinical conclusions. https://www.send2press.com/wire/neurodex-exosort-platform-demonstrates-treatment-responsive-blood-based-measurement-of-neuronal-tdp-43-in-people-living-with-als/

2 · Reply

Market Cap	23.05M
Revenue (ttm)	0.00
Net Income (ttm)	-11.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	57,100
Avg Vol	173,396
Day's Range	N/A - N/A
Shares Out	32.56M
Stochastic %K	13%
Beta	1.58
Analysts	Strong Sell
Price Target	$8.38